Quick Answer
IN8BIO, INC. reported Diluted EPS of $4.44 per share (loss) for fiscal year 2025.
IN8BIO, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.44 | +74.0% |
| 2024 | -$17.05 | -1605.0% |
| 2023 | -$1.00 | +26.5% |
| 2022 | -$1.36 | +7.5% |
| 2021 | -$1.47 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.85 | +81.1% | +31.5% |
| June 30, 2025 | -$1.24 | +77.5% | -1671.4% |
| March 31, 2025 | -$0.07 | +65.0% | +98.4% |
| September 30, 2024 | -$4.49 | -1852.2% | +18.5% |
| June 30, 2024 | -$5.51 | -1940.7% | -2655.0% |
| March 31, 2024 | -$0.20 | +33.3% | +13.0% |
| September 30, 2023 | -$0.23 | +32.4% | +14.8% |
| June 30, 2023 | -$0.27 | +28.9% | +10.0% |
- IN8BIO, INC. showed an increase of +74.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, IN8BIO, INC.’s diluted eps has declined by 202.0% (from $1.47 per share (loss) to $4.44 per share (loss)).
- The most recent figure is from IN8BIO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: